Table 1.
Baseline clinical and laboratory characteristics of the study population.
| HBV-DeCi patients (n=75) | |
|---|---|
| Gender (male/female) | 59/16 |
| Age (y) | 53.0±11.0 |
| Total protein (g/L) | 58.8±8.1 |
| Albumin (g/L) | 28.0±5.2 |
| ALT (U/L) | 38.0(23.0–66.0) |
| AST (U/L) | 56.0(60.0–87.0) |
| Total bilirubin (μmol/L) | 96.0(61.0–203.0) |
| INR | 1.60±0.39 |
| Serum Cr (mmol/L) | 72.0(60.0–99.0) |
| HBsAg, positive | 75 |
| HBeAg, positive | 44 |
| HBcAb IgM, positive | 0 |
| Cystatin C (mg/L) | 1.06(0.90–1.48) |
| MELD score | 17.4(13.7–21.4) |
| Child-Pugh score | 10.0(9.0–11.0) |
| Modes of decompensation | 10.0(9.0–11.0) |
| HE, n (%) | 2(2.7%) |
| HRS, n (%) | 5(6.7%) |
| Ascites, n (%) | 48(64.0%) |
| Variceal bleeding, n (%) | 22 (29.3%) |
Data are expressed as n, mean ± SD, or median (interquartile range).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; Cr, creatinine; HE, hepatic encephalopathy; HRS, hepatorenal syndrome; MELD score, model for end-stage liver disease score.